MX2023006383A - Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo. - Google Patents

Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo.

Info

Publication number
MX2023006383A
MX2023006383A MX2023006383A MX2023006383A MX2023006383A MX 2023006383 A MX2023006383 A MX 2023006383A MX 2023006383 A MX2023006383 A MX 2023006383A MX 2023006383 A MX2023006383 A MX 2023006383A MX 2023006383 A MX2023006383 A MX 2023006383A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
growth factor
connective tissue
tissue growth
factor antibody
Prior art date
Application number
MX2023006383A
Other languages
English (en)
Inventor
Tingting Wu
Xun Liu
Xiazhen Ma
Original Assignee
Jiangsu Hengrui Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Pharmaceuticals Co Ltd filed Critical Jiangsu Hengrui Pharmaceuticals Co Ltd
Publication of MX2023006383A publication Critical patent/MX2023006383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporciona una composición farmacéutica que comprende un anticuerpo anti-factor de crecimiento de tejido conjuntivo. Otro aspecto, que se proporciona adicionalmente, es el uso de la composición farmacéutica que comprende un anticuerpo contra el factor de crecimiento del tejido conjuntivo.
MX2023006383A 2020-12-03 2021-12-03 Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo. MX2023006383A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202011405490 2020-12-03
CN202111366667 2021-11-18
PCT/CN2021/135203 WO2022117060A1 (zh) 2020-12-03 2021-12-03 一种含抗结缔组织生长因子抗体的药物组合物

Publications (1)

Publication Number Publication Date
MX2023006383A true MX2023006383A (es) 2023-06-14

Family

ID=81853824

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023006383A MX2023006383A (es) 2020-12-03 2021-12-03 Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo.

Country Status (11)

Country Link
US (1) US20230416352A1 (es)
EP (1) EP4257603A1 (es)
JP (1) JP2024500311A (es)
KR (1) KR20230117161A (es)
CN (1) CN116391041A (es)
AU (1) AU2021390125A1 (es)
BR (1) BR112023009093A2 (es)
CA (1) CA3200705A1 (es)
MX (1) MX2023006383A (es)
TW (1) TW202227485A (es)
WO (1) WO2022117060A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115645525B (zh) * 2022-12-14 2023-04-14 北京大学第三医院（北京大学第三临床医学院） Ctgf中和抗体在制备防治绝经后骨关节炎的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2010042201A1 (en) * 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of focal segmental glomerulosclerosis
EP2448971A1 (en) * 2009-07-02 2012-05-09 Fibrogen, Inc. Methods for treatment of muscular dystrophy
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
CA2832910C (en) * 2011-04-12 2019-07-02 Cynthia Lander Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
CN104011206B (zh) * 2011-12-22 2017-03-08 安斯泰来制药株式会社 新型抗人ctgf抗体
AU2020262416A1 (en) * 2019-04-24 2021-12-16 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
BR112021023669A2 (pt) * 2019-06-04 2022-03-29 Jiangsu Hengrui Medicine Co Anticorpo do fator de crescimento de tecido anti-conjuntivo e aplicação do mesmo

Also Published As

Publication number Publication date
US20230416352A1 (en) 2023-12-28
BR112023009093A2 (pt) 2024-02-06
TW202227485A (zh) 2022-07-16
WO2022117060A1 (zh) 2022-06-09
AU2021390125A1 (en) 2023-06-22
EP4257603A1 (en) 2023-10-11
CN116391041A (zh) 2023-07-04
KR20230117161A (ko) 2023-08-07
CA3200705A1 (en) 2022-06-09
JP2024500311A (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
TWD203826S (zh) 椅子
TW200531702A (en) Pharmaceutical preparation comprising an antibody against the egf receptor
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
TWD203554S (zh) 酒櫃
ZA202105285B (en) Antibody against human il-4ra and use thereof
TWD206925S (zh) 注射器
TWD214327S (zh) 氣溶膠產生裝置
CR20220329A (es) Anticuerpos anti–mertk y metodos de uso de los mismos
TWD203545S (zh) 椅子
MX2023006383A (es) Composicion farmaceutica que contiene anticuerpo anti-factor de crecimiento de tejido conjuntivo.
SE0300098D0 (sv) Use of cyclin D1 inhibitors
CR20210507A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
TWD204252S (zh) 真空泵
TWD206366S (zh) 錶
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
AU2020344620A8 (en) Implant comprising first and second sets of pillars for attaching a tendon or ligament to a hard tissue
WO2020235974A3 (ko) 단일염기 치환 단백질 및 이를 포함하는 조성물
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
EP3981787A4 (en) ANTIBODIES AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND ITS USE
TWD203407S (zh) 錶
TWD206578S (zh) 戒指
WO2022268857A3 (en) Vhh-based nkp30 binders
TWD209448S (zh) 皮膚治療裝置
TWD208696S (zh) 食物容器